In the following video, Motley Fool health-care analyst David Williamson highlights a potential new threat to an entire class of multibillion-dollar drugs. The drug group, which treats type 2 diabetes, could be linked to pancreatitis, a very serious inflammation of the pancreas that can lead to pancreatic cancer. David tells investors how several companies, such as Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN) could be affected if the link is confirmed, and how serious the damage could be financially.
- Mar 18, 2013 at 6:58PM
- Health Care
- Worried About a Recession? These 3 Stocks Can Help Protect Your Portfolio
- Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?
- These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
- Merck Reports Fantastic Q2 Earnings Results: 4 Things You Need to Know
- Merck & Co Inc (MRK) Q2 2019 Earnings Call Transcript